Reuters logo
BRIEF-Akari ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​
September 21, 2017 / 11:17 AM / 3 months ago

BRIEF-Akari ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

Sept 21 (Reuters) - Akari Therapeutics PLC:

* ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

* Akari Therapeutics PLC says ‍working to initiate a Phase III clinical trial of Coversin‍ following a recent FDA meeting​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below